The Lancet Rheumatology in conversation with
Editors at The Lancet Rheumatology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.
A monthly audio companion to the journal, this podcast covers a broad range of topics, from disorders of the immune system to sex and gender in research design, the transitional care for adolescent patients with rheumatic diseases to care for undocumented immigrants, and more.
The Lancet Rheumatology in conversation with
John Isaacs and Josh Bennett on sarcopenia in rheumatoid arthritis
During this episode, Dr John Isaacs and Dr Josh Bennett from Newcastle University and the NIHR Newcastle Biomedical Research Centre, discuss sarcopenia - an age-related loss of muscle mass and strength. Sarcopenia is relatively common in rheumatoid arthritis, with a prevalence ranging from 4·5% to 44% of people with rheumatoid arthritis, depending on the definition of sarcopenia used. Rheumatoid sarcopenia increases the risk of fall, fractures, disability, and hospitalisation. Therefore, prevention and management is important, especially in older patients. We discuss the how and why sarcopenia arises and how it can be managed, as well as the recent publication of the RAMUS study, which looked at the skeletal muscle effects of JAK inhibitor tofacitinib in rheumatoid arthritis. The link to the Nature Rheumatology Review mentioned can also be found below.
RAMUS study: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00184-5/fulltext
Nature Rheumatology Review: https://www.nature.com/articles/s41584-023-00921-9
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv